Blood Platelet Disorders  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
aHUS, NCT00844844 / 2008-006953-41: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant

Completed
2
1
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
09/10
07/13
aHUS, NCT00844545 / 2008-006952-23: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant

Completed
2
16
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
09/10
07/13
aHUS, NCT00844428 / 2008-006955-28: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive

Completed
2
5
Canada, Europe
eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
10/10
12/13
aHUS, NCT00838513 / 2008-006954-17: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome

Completed
2
15
Canada, Europe
eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
10/10
12/13
NCT01757431: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Completed
2
2
Japan
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
09/13
09/13
NCT01194973 / 2010-020326-18: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Completed
2
44
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic-Uremic Syndrome
10/13
02/14
aHUS, NCT01193348: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Completed
2
22
US, Canada, Europe, RoW
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic-Uremic Syndrome
01/14
04/14
NCT02298933: Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Completed
2
10
US
Eculizumab
National Heart, Lung, and Blood Institute (NHLBI)
Thrombocytopenia, Alloimmune Platelet Refractoriness
08/17
08/17

Download Options